Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and other medications like it have a host of other potential health benefits beyond obesity,

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight.In report published in Nature Medicine,

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications. Experts break down the findings.

GLP-1 medications associated with lower risks of Alzheimer's and heart disease, but higher risks of pancreatitis and kidney problems.